
==== Front
BMC Pulm Med
BMC Pulm Med
BMC Pulmonary Medicine
1471-2466
BioMed Central London

39272042
3277
10.1186/s12890-024-03277-2
Research
Trends in COPD severe exacerbations, and all-cause and respiratory mortality, before and after implementation of newer long-acting bronchodilators in a large population-based cohort
Guay Charles-Antoine charles-antoine.guay.1@ulaval.ca

1234
Maltais François 14
Beaudoin Claudia 2
Carmichael Pierre-Hugues 5
Laouan Sidi Elhadji Anassour 2
Perreault Laurie 1
Sirois Caroline 256
Provencher Steeve 14
1 https://ror.org/04sjchr03 grid.23856.3a 0000 0004 1936 8390 Centre de Recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, 2725, chemin Sainte-Foy, Québec, QC G1V 4G5 Canada
2 https://ror.org/00kv63439 grid.434819.3 0000 0000 8929 2775 Institut national de santé publique du Québec, Québec City, Canada
3 https://ror.org/00kybxq39 grid.86715.3d 0000 0000 9064 6198 Département des sciences de la santé communautaire, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Canada
4 https://ror.org/04sjchr03 grid.23856.3a 0000 0004 1936 8390 Department of Medicine, Université Laval, Québec City, Canada
5 grid.459278.5 0000 0004 4910 4652 Centre d’excellence sur le vieillissement de Québec, Québec, Canada
6 https://ror.org/04sjchr03 grid.23856.3a 0000 0004 1936 8390 Faculty of pharmacy, Université Laval, Québec City, Canada
13 9 2024
13 9 2024
2024
24 45018 5 2024
6 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Little is known about the trends in morbidity and mortality at the population level that followed the introduction of newer once-daily long-acting bronchodilators for COPD. The purpose of the study was to evaluate whether the availability of new bronchodilators was associated with changes in the temporal trends in severe COPD exacerbations and mortality between 2007 and 2018 in the older population with COPD; and whether this association was homogeneous across sex and socioeconomic status classes.

Methods

We used an interrupted time-series and three segments multivariate autoregressive models to evaluate the adjusted changes in slopes (i.e., trend effect) in monthly severe exacerbation and mortality rates after 03/2013 and 02/2015 compared to the tiotropium period (04/2007 to 02/2013). Cohorts of individuals > 65 years with COPD were created from the nationally representative database of the Quebec Integrated Chronic Disease Surveillance System in the province of Quebec, Canada. Whether these trends were similar for men and women and across different socioeconomic status classes was also assessed.

Results

There were 130,750 hospitalizations for severe exacerbation and 104,460 deaths, including 24,457 (23.4%) respiratory-related deaths, over the study period (928,934 person-years). Significant changes in trends were seen after 03/2013 for all-cause mortality (-1.14%/month;95%CI -1.90% to -0.38%), which further decreased after 02/2015 (-1.78%/month;95%CI -2.70% to -0.38%). Decreases in respiratory-related mortality (-2.45%/month;95%CI -4.38% to -0.47%) and severe exacerbation (-1,90%/month;95%CI -3.04% to -0.75%) rates were only observed after 02/2015. These observations tended to be more pronounced in women than in men and in higher socioeconomic status groups (less deprived) than in lower socioeconomic status groups (more deprived).

Conclusions

The arrival of newer bronchodilators was chronologically associated with reduced trends in severe exacerbation, all-cause and respiratory-related mortality rates among people with COPD > 65 years. Our findings document population benefits on key patient-relevant outcomes in the years following the introduction of newer once-daily long-acting bronchodilators and their combinations, which were likely multifactorial. Public health efforts should focus on closing the gap between lower and higher socioeconomic status groups.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12890-024-03277-2.

Keywords

COPD exacerbations
Fixed-dose combination
Interrupted time series
http://dx.doi.org/10.13039/501100000156 Fonds de Recherche du Québec - Santé 331071 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Chronic obstructive pulmonary disease (COPD) remains one of the leading causes of morbidity and mortality worldwide. With an estimated global prevalence of 251 million cases [1], COPD is expected to become the third leading cause of death by 2030 [2]. In the United States alone, COPD generates more than $40 billion in direct annual health care costs, with near 700,000 hospitalizations for severe acute exacerbations (AE-COPD) responsible for most of the economic burden [3–5].

The therapeutic arsenal for COPD has evolved greatly in the last few decades. Long-acting antimuscarinics (LAMAs) and beta2-agonist (LABAs) medications were first introduced in the early 2000’s. More recently, once-daily ultra-long-acting beta2-agonists (ultra-LABAs), newer LAMAs, and fixed-dose combinations (FDCs) of ultra-LABA/LAMA have been introduced. Several clinical studies and meta-analyses have proven the efficacy of each molecule for improving lung function or preventing future COPD exacerbations [6–8]. However, the addition of ultra-LABAs and FDCs have not consistently prevented severe AE-COPD compared the previously available LAMA (tiotropium) and none of the trials documented survival benefit [9–11].

Lower socioeconomic status has been associated with increased hospitalization rates and mortality in patients with COPD [12, 13]. The influence of socioeconomic deprivation on adherence to prescribed medications in COPD has also been questioned [13]. There is also a growing body of evidence supporting important sex and gender differences in COPD susceptibility, disease manifestations, histological pattern and access to new bronchodilators [14–17]. In the context of scarce resources and increasing health inequalities in developed countries, assessment of population effectiveness of new ultra-LABAs/newer-LAMAs and FDCs is needed to justify an extended use of these expansive new molecules and to inform clinical decision-making. Understanding the influence of socioeconomic status and sex/gender is also critical to ensure a fair distribution of public health resources.

We aimed to assess whether the introduction of new bronchodilators influenced the temporal trends in severe COPD exacerbations and mortality among the older COPD population from 2007 to 2018, and to determine if this association varied across different sexes and socioeconomic status classes using population-based data.

Methods

Data source and study design

We used interrupted time-series to compare monthly severe AE-COPD, all-cause and respiratory mortality rates following the introduction of newer once-daily long-acting bronchodilators among older adults with COPD. Data were obtained from the Quebec Integrated Chronic Disease Surveillance System (QICDSS) [18]. Since 1996, this surveillance system has enabled chronic disease monitoring in Quebec, including COPD, by linking provincial health services administrative data using a unique patient identifier. The QICDSS comprises five health administrative databases that include information on registration plans, death registries, and physician service fees. It also contains pharmaceutical claims records obtained from the Provincial health insurance board (Quebec Health Insurance Board [RAMQ]) and it includes hospital discharge abstract records from the hospitalisation databases (Maintenance and Use of Data for the Study of Hospital Clientele [MED-ECHO]) owned by the Quebec Ministry of Health and housed at RAMQ. Demographic data includes place of residence, age, sex and a neighborhood-level social and material deprivation index as an ecological substitute of the socioeconomic status [19]. Data in the QICDSS are updated every fiscal year (fiscal year begins April 1rst and ends March 31rst). Hospital discharge records include the admission diagnosis, primary diagnosis and up to 29 secondary diagnoses coded using the Canadian adaptation of the Tenth Revision of the International Classification of Diseases (ICD-10-CA) system. As the province of Quebec has a universal healthcare system, the QICDSS includes medical records for over 99% of the population ensuring extensive data availability for surveillance and research purposes. The pharmaceutical database provides information on drugs dispensed to individual covered by the province’s public drug insurance plan. In Quebec, drug insurance is mandatory, and all individuals aged 65 and older are eligible for the public drug plan. However, about 10% of these individuals opt for private insurance or receive medication through their nursing home instead.

Finally, the QICDSS incorporates the material and social deprivation index, a composite index that measures material and social deprivation at the ecological level, serving as a proxy for socioeconomic status [19]. It integrates indicators from the Canadian census such as income, employment, education, and family structure to provide a comprehensive assessment of deprivation within communities. Each dimension of the index is divided in quintile depending on the score for each component. A higher deprivation index is associated with a lower SES which has been previously validated in the adult population in Quebec [19].

This study was reviewed and approved by the Laval University institutional review board (2021 − 271).

Study population and periods

We restricted our population to individuals 66 years and older to ensure comprehensive coverage from our dataset (> 90% of the older population in Quebec is covered by the public health and drug plans) [18]. It also maximised the positive predictive value of COPD case-definition since the prevalence of this disease increases with age [20]. A diagnosis of COPD was defined as either ≥ 1 diagnosis of COPD registered within the hospitalization database (primary or secondary, Supplementary Table 1); or ≥ 3 diagnoses of COPD registered in the physician claims database within the last three years. This validated algorithm has a sensitivity of 59.3% (95%CI:49.7–68.4), a specificity of 95.4% (95%CI:92.6–97.4), and a positive predictive value of 81.7% (95%CI:71.6–89.4) in adults over the age of 35 [21]. No exclusion criteria were applied. We constructed monthly cohorts using data at the individual level (Supplementary Fig. 1) based on the individual fulfilment of the case definition for that month, allowing us to further reduce the number of false positive cases.

We used data from April 1st 2007 to August 31st 2018 to avoid historical bias from the transition in the ICD revision used in the QICDSS (from ICD-9 to ICD-10 codes in 2006), from the introduction of the ultra-LABA/LAMA/corticosteroids single inhaler in Quebec (09/2018) and from the COVID-19 pandemic [18, 22]. Given that ultra-LABAs and newer-LAMAs were launched simultaneously, three distinct segments were determined by the date when ultra-LABAs and FDCs were first approved and covered by the public drug plan, separating the tiotropium period (04/2007 to 02/2013), the post-ultra-LABAs (03/2013 to 01/2015) and the post-FDCs (02/2015 to 08/2018) periods.

Outcomes

The primary outcome was the monthly rate of severe AE-COPD (requiring hospitalization). Only cases with a primary diagnosis of AE-COPD in the hospitalization database were retained in primary analyses (Supplementary Table 1). A washout period of 14 days between two severe AE-COPD was used to avoid misclassification of relapsing AE-COPD. Secondary outcomes included monthly rates of all-cause and respiratory mortality, the later defined as a primary cause of death associated with diseases of the respiratory system in the death registry.

Statistical analysis

For each outcome, we calculated monthly incidence rates by dividing the number of new severe AE-COPD, all-cause or respiratory-related deaths by the person-time at risk over the month. We then used three segments multivariate autoregressive models to evaluate changes in slopes (i.e., trend effect) after 03/2013 and 04/2015 compared to the tiotropium period (04/2007 to 02/2013). We did not test for an abrupt change in the level of severe AE-COPD after ultra-LABAs/newer-LAMAs and FDCs introduction since they were introduced progressively after their arrival on the market [23]. We included a season term in the model to account for a simple seasonality pattern of peak in AE-COPD incidence during winter and nadir in summer [14, 24]. Major confounding factors identified graphically using a directed acyclic graph of the relationship between the introduction of ultra-LABAs/newer LAMAs and FDCs and severe COPD exacerbations were accounted for in the regression analyses. They included age, sex, past exacerbations, comorbidities prevalence, medications for COPD (including inhaled corticosteroids in monotherapy/combination), material deprivation, social deprivation and region of residence. Other individual-level confounders identified graphically were not included in the statistical analyses because of their unavailability in the data sources (e.g., smoking status, COPD severity, occupational exposure and vaccination status) and their tendency to change only slowly over time (Supplementary Fig. 2). In the statistical models, age is defined as the average age of individuals in the monthly cohorts, based on their age at the start of the fiscal year. Sex is represented by the proportion of women in these cohorts. Past exacerbations are quantified by the proportion of individuals who have had at least one moderate to severe exacerbation in the past year, with moderate exacerbations defined as those requiring antibiotic or prednisone treatment for 5 to 14 consecutive days in the physician claims database. Comorbidities prevalence is the average number of comorbidities among cohort members (the list of diseases of interest and ICD-codes are available in Supplementary Table 1). COPD medication use includes short-acting and long-acting bronchodilators, inhaled corticosteroids (either as monotherapy or in combination), smoking cessation medication, and macrolide prophylaxis. Drug utilization was defined by at least one billing in the previous 12 months in the pharmaceutical database. Material and social deprivation are measured by the proportion of individuals in each quintile of their respective indices. Finally, region of residence is defined as the proportion of the population living in rural areas. Terms with marginal month-to-month variation were excluded from the final models to avoid collinearity issues. We conducted stratified analyses according to sex and socioeconomic status quintiles using the material deprivation index incorporated in the QICDSS [18, 19].

In sensitivity analyses, we used a second case definition maximising sensitivity over specificity, defining COPD as either ≥ 1 diagnosis of COPD registered to the hospitalization database or ≥ 1 diagnosis of COPD registered to the physician claims database in an unspecified time period. This algorithm has been validated with a sensitivity of 85.0% (95%CI:77.0–91.0), a specificity of 78.4% (95%CI:73.6–82.7) and a positive predictive value of 57.5% (95%CI:49.6–65.1) in adults over the age of 3521. We also performed interrupted time-series analyses with different change points to test the robustness of the model. Based on the estimated number needed to treat to prevent one severe AE-COPD of 11 over a 12-month period [8], the selected change points correspond to the date when 10% of COPD cases were ultra-LABAs/newer-LAMAs users (04/2015) or FDCs users (02/2018). All analyses were performed with SAS statistical software (version 9.4; SAS institute, Inc), with 95% confidence-intervals computed using a 5% level of statistical significance. Complete data analyses were performed using population aggregates at each time point, with the QICDSS providing extensive coverage of our studied population and only minimal (< 10%) missing individual data [19]. We did not adjust for multiplicity.

This study followed the RECORD-PE reporting guidelines for pharmacological research using observational routinely collected health data [25].

Results

Study population

There were 130,750 hospitalizations for severe AE-COPDs and 104,460 deaths, including 24,457 (23.4%) respiratory-related deaths, over the study period (928,934 person-years). Characteristics of the study cohorts remained similar over the years, except for slight increases in age, women proportion and mean number of comorbidities (Table 1). The proportion of ultra-LABAs/newer-LAMAs’ and FDCs users increased steadily after 03/2013 and 02/2015, respectively, to reach 18.4% and 13.5% by the end of the study period (Fig. 1). The proportion of ultra-LABAS/newer-LAMAs users tended to be lower in less deprived subgroups (Supplementary Fig. 3), whereas the proportions of ultra-LABAS/newer-LAMAs and FDCs users were numerically lower in women (Supplementary Fig. 4).

Table 1 Baseline characteristics of COPD patients between April 2007 and August 2018

	Pre-ultra-LABAs/newer LAMAs period (April 2007- February 2013)	Post-ultra-LABAs/newer LAMAs period (March 2013- January 2015)	Post-FDCs period (February 2015- August 2018)	
N = 64,161	N = 76,759	N = 79,401	
Agea (mean ± SD), years	77.6 (± 7.0)	77.9 (± 7.4)	78.0 (± 7.5)	
Sex				
 Men	33,398 (52.1)	37,900 (49.4)	39,070 (49.2)	
 Women	30,763 (47.9)	38,859 (50.6)	40,331 (50.8)	
Past exacerbation (moderate-to-severe)b in the previous year				
 Yes	10,963 (17.1)	11,784 (15.4)	12,517 (15.8)	
 No	53,198 (82.9)	64,975 (84.6)	66,884 (84.2)	
Comorbiditiesc (mean ± SD)	5.43 (± 3.3)	5.61 (± 3.4)	5.79 (± 3.5)	
 Diabetes	17,879 (27.9)	23,413 (30.5)	24,581 (31.0)	
 Heart failure	15,958 (24.9)	17,217 (22.4)	18,189 (22.9)	
 Hypertension	44,135 (68.8)	54,723 (71.3)	56,933 (71.7)	
 Obesity	7,007 (10.9)	9,087 (11.8)	10,014 (12.6)	
Medication				
 Short-acting bronchodilators	30,610 (47.7)	47,035 (61.3)	48,140 (60.6)	
  SABAs	28,502 (44.4)	46,162 (60.1)	47,377 (59.7)	
  SAMAs	7,772 (12.1)	4,954 (6.5)	4,200 (5.3)	
 Long-acting bronchodilators	23,220 (36.2)	40,400 (52.6)	40,389 (50.8)	
  LABAsd	14,105 (22.0)	6,666 (8.7)	5,768 (7.3)	
  Tiotropium	14,720 (22.9)	38,448 (50.1)	38,639 (48.7)	
 Ultra-LABAs/Newer-LAMAs	0 (0.00)	0 (0.00)	6,949 (8.75)	
  Ultra-LABAs	0 (0.00)	0 (0.00)	2,993 (3.77)	
  Newer-LAMAs	0 (0.00)	0 (0.00)	5,632 (7.09)	
 FDCs	0 (0.00)	0 (0.00)	0 (0.00)	
 ICS	41,326 (64.4)	50,750 (66.1)	51,857 (65.3)	
 Methylxanthines	3,895 (6.1)	2,236 (2.9)	1,799 (2.3)	
 Smoking cessation treatments	4,012 (6.3)	6,210 (8.1)	6,465 (8.1)	
Material deprivation				
 1st quintile (least deprived)	7,379 (11.5)	8,340 (10.9)	7,959 (10.0)	
 2nd quintile	9,848 (15.3)	11,470 (14.9)	10,492 (13.2)	
 3rd quintile	11,897 (18.5)	13,720 (17.9)	13,673 (17.2)	
 4th quintile	14,164 (22.1)	16,089 (21.0)	16,110 (20.3)	
 5th quintile (most deprived)	16,623 (25.9)	17,946 (23.4)	19,335 (24.4)	
 Missing valuese	4,250 (6.6)	9,194 (12.0)	11,832 (14.9)	
Region of residence				
 Rural (< 10 000 inhabitants)	16,609 (25.9)	19,227 (25.1)	19,560 (24.7)	
 Urban (≥ 10 000 inhabitants)	47,421 (74.1)	57,428 (74.9)	59,739 (75.3)	
aAge at the beginning of the current fiscal year. bModerate exacerbations were defined as COPD exacerbation in the physician claims database requiring antibiotic or prednisone (any dose) treatment for at least five consecutive days and no more than 14 consecutive days. cAverage number of comorbidities in individuals contributing to monthly cohorts. dSalmeterol and formoterol. eSources of missing data include invalid zip codes, cases living in long term care facilities or in nursing homes and areas not cover by the material and social deprivation index (mostly isolated rural regions). Abbreviations: FDC = Fixed dual dose combinations; ICS = Inhaled corticosteroids; LABA = Long-acting beta2-agonist; LAMA = Long-acting antimuscarinics; SABA = Short-acting B2-agonist; SAMA = Short-acting antimuscarinics; SD = standard deviation

Fig. 1 Proportion of ultra-LABAs/newer-LAMAs and FDC users between April 2007 and August 2018. The first ultra-LABAs (indacaterol) was introduced on the list of drugs covered by the public drug plan in February 2013 and was first reimbursed in March 2013. The first FDC (indacaterol/glycopyrronium) was introduced on the list of drugs covered by the public drug plan in February 2015 and was first reimbursed in February 2015. Listed ultra-LABAs/newer-LAMAs in the public drug plan: indacaterol (ultra-LABA), glycopyrronium and umeclidinium (newer-LAMAs). Listed FDCs in the public drug plan: indacaterol/glycopyrronium, vilanterol/umeclidinium, olodaterol/tiotropium

Severe AE-COPD

Visual inspection revealed a clear seasonal pattern in monthly severe AE-COPD rate (Fig. 2). An upward trend (+ 0.55%/month;95%CI 0.17–0.94) was observed in severe AE-COPD incidence from 04/2007 to 02/2013 (Table 2). In the segmented regression model, only the introduction of FDCs was associated with significantly sustained decrease in severe AE-COPD rate (-1,90%/month;95%CI -3.04% to -0.75%) (Table 2). Baseline severe AE-COPD rates were higher amongst patients with the lowest socioeconomic status (Table 2, Supplementary Fig. 5), but similar for men and women (Table 3, Supplementary Fig. 6). The reduction tended to be higher in the second and third quintiles of the materially deprived population (Table 2, Supplementary Fig. 5) and in women (Table 3, Supplementary Fig. 6).

Fig. 2 Severe AE-COPD and mortality trends before and after the introduction of ultra-LABAs/newer-LAMAs and FDCs. Vertical dashed line indicates March 2013 when ultra-LABAs/newer LAMAs were introduced in Quebec, Canada. Grey areas show the period from March 2013 (ultra-LABAs/newer-LAMAs’ introduction) to February 2015 (FDCs’ introduction). Solid regression lines show the observed adjusted trends after the introduction of ultra-LABAs/newer-LAMAs and FDCs, whereas dashed regression lines are the predicted adjusted trends after March 2013 assuming no change in the trends observed before introduction of new bronchodilators. AE-COPD = acute exacerbation of chronic obstructive pulmonary disease; ultra-LABA = ultra-long-acting beta2-agonist; LAMA = long-acting antimuscarinic; FDC = fixed-dose combinations

Table 2 Association between the introduction of ultra-LABAs/newer-LAMAs and FDCs and severe AE-COPD and mortality trends – interrupted time series analyses

		Introduction of ultra-LABAs/newer-LAMAs		Introduction of FDCs			
Outcome	Mean monthly rate per 1,000 person-years in 2007 (95% CI)	Trend before March 2013, % (95% CI)a	Monthly % change after March 2013 (95% CI)a	P valuea	Monthly % change after February 2015 (95% CI)a	P valuea		
Overall									
 Severe AE-COPD	120.49 (104.95 to 136.02)	0.55 (0.17 to 0.94)	0.66 (-0.14 to 1.45)	0.11	-1.90 (-3.04 to -0.75)	0.001		
 All-cause mortality	105.08 (98.69 to 111.47)	0.85 (0.50 to 1.22)	-1.14 (-1.90 to -0.38)	0.004	-1.78 (-2.70 to -0.38)	< 0.001		
 Respiratory-related mortality	23.87 (20.57 to 27.16)	0.76 (0.15 to 1.37)	-0.17 (-1.52 to 1.19)	0.80	-2.45 (-4.38 to -0.47)	0.02		
Material deprivation								
1st quintile (least deprived)								
 Severe AE-COPD	96.82 (79.96 to 113.68)	0.27 (-0.20 to 0.74)	0.99 (0.04 to 1.93)	0.04	-0.76 (-2.02 to 0.52)	0.24		
 All-cause mortality	103.86 (89.00 to 118.73)	0.62 (0.30 to 0.95)	-0.55 (-0.93 to -0.17)	0.005	-0.68 (-1.49 to 0.12)	0.10		
 Respiratory-related mortality	23.75 (18.19 to 29.31)	0.63 (-0.13 to 1.40)	-0.43 (-1.42 to 0.57)	0.40	-1.40 (-3.25 to 0.49)	0.14		
2nd quintile								
 Severe AE-COPD	112.39 (92.43 to 132.36)	1.14 (0.63 to 1.66)	-1.74 (-2.98 to -0.48)	0.007	-1.01 (-1.92 to -0.09)	0.03		
 All-cause mortality	107.02 (96.41 to 117.63)	0.58 (0.14 to 1.02)	-0.90 (-1.98 to 0.20)	0.10	-0.78 (-1.56 to 0.01)	0.05		
 Respiratory-related mortality	24.17 (19.90 to 28.45)	1.40 (0.52 to 2.29)	-2.41 (-4.51 to -0.26)	0.03	-1.87 (-3.41 to -0.32)	0.02		
3rd quintile								
 Severe AE-COPD	120.15 (104.05 to 136.25)	0.21 (-0.19 to 0.61)	0.64 (-0.41 to 1.70)	0.23	-0.94 (-1.90 to 0.02)	0.06		
 All-cause mortality	102.87 (90.32 to 115.41)	0.44 (0.15 to 0.74)	-0.99 (-1.69 to -0.29)	0.006	-0.72 (-1.39 to -0.03)	0.04		
 Respiratory-related mortality	22.40 (17.29 to 27.50)	0.31 (-0.19 to 0.82)	-0.18 (-1.46 to 1.12)	0.78	-1.71 (-2.89 to -0.50)	0.01		
4th quintile								
 Severe AE-COPD	122.04 (103.39 to 140.68)	0.28 (-0.26 to 0.81)	-0.07 (-1.18 to 1.05)	0.90	-0.41 (-1.47 to 0.66)	0.45		
 All-cause mortality	98.64 (91.63 to 105.64)	0.03 (-0.24 to 0.30)	-0.17 (-0.74 to 0.40)	0.56	-0.21 (-0.74 to 0.33)	0.44		
 Respiratory-related mortality	21.87 (17.51 to 26.24)	0.09 (-0.45 to 0.63)	-0.19 (-1.28 to 0.91)	0.74	-0.73 (-1.75 to 0.30)	0.16		
5th quintile (most deprived)								
 Severe AE-COPD	134.75 (120.74 to 148.75)	-0.31 (-0.59 to -0.03)	1.29 (0.68 to 1.90)	< 0.001	-0.08 (-0.79 to 0.64)	0.83		
 All-cause mortality	104.64 (97.01 to 112.27)	0.05 (-0.17 to 0.26)	-0.15 (-0.63 to 0.33)	0.53	-0.21 (-0.74 to 0.33)	0.45		
 Respiratory-related mortality	23.74 (19.77 to 27.71)	0.14 (-0.35 to 0.63)	-0.20 (-1.29 to 0.90)	0.72	-0.42 (-1.64 to 0.82)	0.51		
aFinal model adjusted for age, sex, prior exacerbations (moderate-to-severe) in the previous year, comorbidities, current use of short-acting bronchodilators, long-acting bronchodilators, inhaled corticosteroids, smoking cessation medication and macrolide prophylaxis, material deprivation, social deprivation, rural area (< 10 000 inhabitants), seasonality and residual autocorrelation. Individuals with missing socioeconomic status value were excluded from stratified analyses

Abbreviations: AE-COPD = acute exacerbation of chronic obstructive pulmonary disease

Table 3 Association between the introduction of ultra-LABAs/newer-LAMAs and FDCs and severe AE-COPD and mortality trends according to sex

		Introduction of ultra-LABAs/newer-LAMAs		Introduction of FDCs		
Outcome	Mean monthly rate per 1,000 person-years in 2007 (95% CI)	Trend before March 2013, % (95% CI)a	Monthly % change after March 2013 (95% CI)a	P valuea	Monthly % change after February 2015 (95% CI)a	P valuea	
Overall		
 Severe AE-COPD	120.49 (104.95 to 136.02)	0.55 (0.17 to 0.94)	0.66 (-0.14 to 1.45)	0.11	-1.90 (-3.04 to -0.75)	0.001	
 All-cause mortality	105.08 (98.69 to 111.47)	0.85 (0.50 to 1.22)	-1.14 (-1.90 to -0.38)	0.004	-1.78 (-2.70 to -0.38)	< 0.001	
 Respiratory-related mortality	23.87 (20.57 to 27.16)	0.76 (0.15 to 1.37)	-0.17 (-1.52 to 1.19)	0.80	-2.45 (-4.38 to -0.47)	0.02	
Men							
 Severe AE-COPD	121.52 (105.87 to 137.20)	0.59 (0.22 to 0.96)	0.47 (-0,28 to 1.22)	0.22	-1.32 (-2.55 to -0.07)	0.04	
 All-cause mortality	115.62 (108.92 to 122.30)	0.64 (0.25 to 1.02)	-1.06 (-1.85 to -0.28)	0.01	-1.67 (-2.82 to -0.52)	0.01	
 Respiratory-related mortality	25.96 (22.54 to 29.39)	0.55 (-0.05 to 1.15)	-0.67 (-1.93 to 0.60)	0.29	0.49 (-1.64 to 2.68)	0.65	
Women							
 Severe AE-COPD	119.36 (102.86 to 135.85)	0.46 (-0.05 to 0.97)	0.80 (-0.24 to 1.85)	0.13	-2.19 (-3.52 to -0.85)	0.002	
 All-cause mortality	93.76 (84.84 to 102.67)	0.76 (0.38 to 1.13)	-0.24 (-0.99 to 0.51)	0.52	-2.31 (-3.38 to -1.24)	< 0.001	
 Respiratory-related mortality	21.61 (17.89 to 25.34)	1.27 (0.45 to 2.10)	0.23 (-1.45 to 1.93)	0.79	-5.06 (-7.23 to -2.83)	< 0.001	
aFinal model adjusted for age, sex, prior exacerbations (moderate-to-severe) in the previous year, comorbidities, current use of short-acting bronchodilators, long-acting bronchodilators, inhaled corticosteroids, smoking cessation medication and macrolide prophylaxis, material deprivation, social deprivation, rural area (< 10 000 inhabitants), seasonality and residual autocorrelation

Abbreviations: AE-COPD = acute exacerbation of chronic obstructive pulmonary disease

Mortality

All-cause and respiratory-related mortality rates were also characterized by seasonality (Fig. 2). Upward trends were observed in both all-cause and respiratory-related mortality rates from 04/2007 to 02/2013. Significant changes in trends were seen after the introduction of ultra-LABAs/newer-LAMAs for all-cause mortality, which further decreased after FDCs’ introduction. A significant reduction in respiratory-related monthly mortality rate was only seen after the introduction of FDCs. All-cause and respiratory-related mortality rates were comparable across the diverse socioeconomic status (Table 2, Supplementary Fig. 5), but higher in men (Table 3, Supplementary Fig. 6). Changes in trends for all-cause and respiratory-related mortality rates tended to differ according to socioeconomic status, with more prominent reductions in all-cause and respiratory mortality seen in higher socioeconomic status (less deprived) groups (Table 2, Supplementary Fig. 5) and in women (Table 3, Supplementary Fig. 6).

Sensitivity analyses

Similar results were observed when using the case-definition maximising sensitivity over specificity, with reduction in trends for AE-COPD, all-cause and respiratory-related mortality being observed after FDCs introduction only (Supplementary Table 2). Finally, the interrupted time series analysis with change points based on the proportion of users showed significant changes in trends for all outcomes after the proportion of users of ultra-LABAs/newer-LAMAs reached 10% (04/2015), with no additional change in trends after the proportion of users of FDCs reached 10% (02/2018, Table 4).

Table 4 Association between the introduction of ultra-LABAs/newer LAMAs and FDCs and severe AE-COPD and mortality trends – change points based on the proportion of users reaching 10% for ultra-LABAs/newer-LAMAs and FDCs

		10% users of
ultra-LABAs/newer LAMA		10% users of FDCs		
Outcome	Mean monthly rate per 1,000 person-years in 2007 (95% CI)	Trend before April 2015 (95% CI)a	Monthly % change after April 2015 (95% CI)a	P valuea	Monthly % change after February 2018 (95% CI)a	P valuea	
Overall										
 Severe AE-COPD	120.49 (104.95 to 136.02)	0.64 (0.36 to 0.92)	-1.23 (-2.40 to -0.04)	0.04	-0.81 (-2.60 to 1.00)	0.37	
 All-cause mortality	105.08 (98.69 to 111.47)	0.39 (0.19 to 0.59)	-1.78 (-2.71 to -0.85)	< 0.001	1.72 (-0.04 to 3.51)	0.06	
 Respiratory-related mortality	23.87 (20.57 to 27.16)	0.63 (0.19 to 1.08)	-2.42 (-4.38 to -0.42)	0.02	1.17 (-2.12 to 4.56)	0.49	
aFinal model adjusted for age, sex, prior exacerbations (moderate-to-severe) in the previous year, comorbidities, current use of short-acting bronchodilators, long-acting bronchodilators, inhaled corticosteroids, smoking cessation medication and macrolide prophylaxis, material deprivation, social deprivation, rural area (< 10 000 inhabitants), seasonality and residual autocorrelation

Abbreviations: AE-COPD = acute exacerbation of chronic obstructive pulmonary disease

Discussion

This nationally representative data indicates sustained reduced trends in severe AE-COPD, all-cause and respiratory-related mortality adjusted rates after 02/2015 in patients with COPD over 65 years. Interestingly, the timing of the observed reductions corresponds to both the introduction of FDCs (02/2015) and the 10% milestone in ultra-LABAs/newer-LAMAs users (04/2015).

Several clinical trials and meta-analyses have demonstrated greater lung function improvements and symptom reduction with FDCs compared to ultra-LABAs/newer-LAMAs alone irrespective of disease severity [9, 10, 26–28]. Since lung function and dyspnea persistence strongly predict future exacerbations and mortality, it can be argued that the introduction of FDCs could lead to reduced trends in severe AE-COPD and mortality rates [29]. Yet, head-to-head trials assessing comparative efficacy of ultra-LABAs/newer-LAMAs and FDCs found inconclusive results regarding severe AE-COPD and mortality9–11−15,28. The SPARK trial was the first trial specifically designed to assess the efficacy of FDC compared to two LAMAs in preventing exacerbations in moderate-to-severe COPD patients for 64 weeks [10]. The combination of indacaterol/glycopyrronium was associated with a 12% risk reduction in moderate-to-severe exacerbations compared to glycopyrronium alone, whereas no significant difference was noted with tiotropium alone. Subsequent meta-analyses of studies comparing FDCs versus LAMAs resulted in similarly inconclusive results [9, 27], whereas FDCs were associated with a 18% risk reduction moderate-to-severe exacerbations compared to LABAs alone in trials that used a twice-daily LABAs as comparator [27]. Finally, trials comparing FDCs to indacaterol, the only ultra-LABA marketed as monotherapy in the province of Quebec, did not assess exacerbation rates as an outcome [30, 31].

Individual clinical trials most commonly have a limited sample size, precluding valid conclusion regarding the added benefit of novel therapies on relatively infrequent clinical outcomes over already effective therapies. To overcome this limitation, large-scale meta-analyses incorporating data from 51 to 99 studies were recently published [27, 28]. The former suggested that LAMA/LABA may be associated with a small increase in the risk of major adverse cardiovascular events [27], whereas the latter suggested no impact of FDCs on mortality rates [28]. While randomized controlled trials and subsequent meta-analyses are essential to document the efficacy and safety of novel therapies, they are characterized by strict eligibility criteria resulting in participants with limited comorbidities and drug-drug interactions, and a very close clinical follow-up of relatively short duration. For example, there were only 110 total deaths amongst the 101,311 patients contributing to the large-scale meta-analysis described above [28], questioning the external validity of their findings. Conversely, the assessment of real-world effectiveness aims to capture the full spectrum of a disease in the context of the routine delivery of care and may significantly differ from clinical trial-based efficacy [32]. For instance, a real world non-interventional study found a 21% risk reduction in severe AE-COPD with FDCs compared to ultra-LABAs/newer-LAMAs monotherapy after adjusting for disease severity and baseline demographic using propensity score matching [33]. Although residual confounding could not be completely excluded, these results suggest that randomized controlled trials may not provide a definitive answer regarding he comparative effectiveness of FDCs versus to ultra-LABAs/newer LAMAs.

In interrupted time series, observations on a population taken at multiple times before and after an intervention are used to assess a change in trend caused by the intervention. The pre-intervention trend is used to estimate the counterfactual scenario in which the intervention had not occurred, offering the advantage over the non-equivalent group control design for controlling for confounding due to between-group differences and underlying trends in the outcome [34]. It also elegantly avoids confounding by indication, which is a significant challenge in measuring COPD treatment effectiveness in real-world situations, since time is the exposure of interest and is not affected by disease severity [34]. In addition, the routinely collected data allow a more detailed assessment of the longitudinal effects of an intervention than typical clinical trials, in addition to stronger external validity [22, 34]. Nevertheless, time series design can be affected by time-varying confounders that may change rapidly over time. Accordingly, important risk factors for severe AE-COPD were included in our final models to strengthen the robustness of our analyses. Mainly, all statistical models were adjusted for ICS use, either as monotherapy or in combination therapy, to account for the fluctuations in ICS prescription patterns over the study period, reflecting the evolving evidence of their benefits on severe COPD exacerbations and mortality [35]. However, in the absence of randomization, the significant changes in trends we observed cannot be specifically inferred to ultra-LABAs/newer-LAMAs or FDCs. Moreover, interrupted time series may be affected by historical bias when another intervention or event occurs at the time of the time-series interruption and may also affect the outcome of interest [22]. Major potential violators of this assumption including the introduction of single inhaler ultra-LABA/LAMA/inhaled corticosteroids triple therapy and the COVID-19 pandemic occurred after the end of the study period and should not affect our results [35]. Also, the overall management of COPD patients has evolved significantly over the past decades, including pulmonary rehabilitation and self-management programs which have been shown to positively impact the rate of severe AE-COPD and have gained in popularity [36, 37], may have contributed to the overall improvement in COPD outcomes observed in our study [38]. Other significant breakthroughs include an increase in outpatient management of exacerbations, improved smoking cessation programs, and enhanced personalized pharmaceutical approaches based on a better understanding of the risk factors for disease progression [4]. The ecological design of the study makes it impossible to distinguish the independent contribution of each of these factors and the introduction of the new bronchodilators on the observed changes in trends for the whole study period. Nevertheless, the consistency of the sensitivity analyses supports the validity of our results. In addition, our findings suggest a greater impact of the availability of new bronchodilators on severe AE-COPD and respiratory-related mortality compared with all-cause mortality, adding to the biological plausibility of the observed associations.

This work also adds to the existing literature about the association between socioeconomic status and outcomes in COPD and other chronic diseases [38–41], including progressively higher rates of severe AE-COPD rates within low socioeconomic status. We observed a similar or slightly higher proportion of users of new bronchodilators in lower socioeconomic status groups, suggesting similar access to medical care, hospitalization and newer therapies in these patients potentially explained by the universal healthcare system in Canada. Nevertheless, patients in lower socioeconomic groups tended to have smaller reductions in severe AE-COPD, all-cause, and respiratory-related mortality after the introduction of FDCs. Whether this is related to a lower adherence to medications or residual confounding could not be assessed. We also found important sex difference in the trend change in COPD outcomes, with benefit being predominantly observed amongst women. Few clinical studies have assessed the differential treatment response to bronchodilators according to sex and gender [42, 43]. A pooled analysis of six trials from the IGNITE program reported larger improvements in health status and overall symptoms in women than men but authors did not report significant differences in lung function improvements [42]. Although clinical evidence of differences in treatment response is lacking, there is a growing body of evidence supporting important sex and gender differences in COPD disease mechanisms and manifestations [14–16]. In addition of divergent smoking habits, women appear to have a greater susceptibility to COPD with lower tobacco exposure and might be less adherent to medication [15, 16]. Moreover, the histological pattern of COPD differs in women with relatively less emphysema and more small airways disease [17]. These differences could influence treatment response and highlight the need to assess sex-related differences in treatment efficacy in future clinical trials.

This study has some limitations. First, the presence of COPD was not clinically confirmed using spirometry introducing a risk of misclassification bias. Spirometry is essential for accurate COPD diagnosis, and its absence can lead to both overdiagnosis and underdiagnosis of the condition [44]. In the context of our study, the accumulation of false positive cases over time for a lifelong diagnosis like COPD could have biased our inferences about the intervention effect on a population with a high prevalence of individuals not at risk of the outcome. Additionally, without post-bronchodilator spirometry, some false positive cases may have actually had asthma instead of COPD, while others may have had Asthma-COPD Overlap Syndrome (ACOS), with evidence suggesting ACOS could have a distinct phenotype and a different treatment response compared to other COPD patients [45]. However, the impact on our results is likely minimal since we used a consistent case definition throughout the study, minimizing the risk of differential misclassification. To further mitigate the impact of false positive cases, we employed an algorithm with high specificity and positive predictive value [17] and included repeated fulfillment criteria to ensure COPD diagnosis stability over time, thereby minimizing the risk of misclassification between asthma and COPD. Conversely, low sensitivity can lead to missed COPD cases, particularly in low socioeconomic status groups for whom limited healthcare access is still a major determinant of health inequalities [46] or patients with less severe COPD at lower risk of repeated medical consultations and hospitalizations. Over time, improved healthcare access and increased awareness of COPD may have led to the identification of more mild COPD cases, potentially biasing results towards an intervention effect. However, sensitivity analyzes using a case definition with higher sensitivity, which reduced the difference in the number of less severe COPD patients, did not yield different results. Second, we could not assess the impact of the introduction of ultra-LABAs/newer LAMAs, and FDCs in specific subgroups of interest, such as individuals with ACOS, nor according to COPD severity due to the absence of spirometry data or validated algorithms to accurately identify these patients; this should be the subject of further study. Third, interpretation of our results as evidence of individual improvement should be done with caution due to the design of our study and the inherent risk of ecological fallacy. Finally, our results may not be generalizable to younger COPD patients, those with private drug insurance and institutionalized individuals, and to less severe outcomes such as mild to moderate exacerbations. Nevertheless, our study provides reassuring results in an older population that is often underrepresented in clinical trials.

Conclusion

In conclusion, the introduction of newer long-acting bronchodilators was chronologically associated with reduced adjusted trends in severe AE-COPD, all-cause and respiratory-related mortality rates in the older COPD population. Taken together, our findings suggest potential population benefits on key patient-relevant outcomes in the years following the introduction of ultra-LABAs/newer LAMAs and FDCs in COPD patients > 65 years of age. Whether the changes in trends are due to a higher proportion of ultra-LABA/newer LAMA users, the introduction of FDCs, or simply the overall improvement in COPD management remains to be confirmed. The observed sex- and socioeconomic status-related differences in the changes in these trends support the need for prospective clinical trials adequately powered for sex/gender-specific analyses, as well as public health efforts focused on closing the gap between lower and higher socioeconomic groups.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Acknowledgements

None.

Author contributions

Concept and design: Guay, Maltais, Beaudoin, Carmichael, Sirois, Provencher. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Guay, Provencher. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Guay, Carmichael, Laouan Sidi. Supervision: Sirois, Provencher.

Funding

Charles-Antoine Guay received a grant from the Fonds de recherche du Québec – Santé (FRQ-S) for this work.

Data availability

The datasets generated and analysed during the study are not publicly available due to individual privacy stakes. The data are stored on a secure server and regulated by the Quebec Ministry of Health and the Quebec Health Insurance Board. Access to the data is restricted to authorized personnel only to prevent any sensitive data breaches.

Declarations

Ethics approval and consent to participate

This study involved aggregated human data and do not contains any individual person’s data. This study was reviewed and approved by the Laval University institutional review board (2021 − 271).

Consent for publication

Not applicable.

Competing interests

Charles-Antoine Guay reports financial support was provided by Quebec Health Research Fund. Francois Maltais reports a relationship with GlaxoSmithKline that includes: funding grants and speaking and lecture fees. Francois Maltais reports a relationship with AstraZeneca that includes: consulting or advisory and funding grants. Francois Maltais reports a relationship with Sanofi that includes: funding grants. Francois Maltais reports a relationship with Novartis that includes: funding grants and speaking and lecture fees. Francois Maltais reports a relationship with Boehringer Ingelheim that includes: funding grants and speaking and lecture fees. Francois Maltais reports a relationship with Grifols that includes: funding grants and speaking and lecture fees. Francois Maltais reports a relationship with Oxynov that includes: equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Footnotes

None.

Abbreviations

ACOS Asthma-COPD Overlap Syndrome

AE-COPD Acute exacerbation of COPD

CI Confidence interval

COPD Chronic obstructive pulmonary disease

FDC Fixed dual doses combination

ICD-9 International Classification of Diseases, 9th Revision

ICD-10 International Classification of Diseases, 10th Revision

ICD-10-CA International Classification of Diseases, 10th Revision, Canada

ICS Inhaled corticosteroids

LABA Long-acting beta2-agonist

LAMA Long-acting antimuscarinics

MED-ECHO Maintenance and Use of Data for the Study of Hospital Clientele

QICDSS Quebec Integrated Chronic Disease Surveillance System

RAMQ Quebec Health Insurance Board

SABA Short-acting B2-agonist

SAMA Short-acting antimuscarinics

ultra-LABA Ultra-long-acting beta2-agonist

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Caroline Sirois and Steeve Provencher are co-senior authors.
==== Refs
References

1. Vos T Lim SS Abbafati C Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019 Lancet 2020 396 10258 1204 22 10.1016/S0140-6736(20)30925-9 33069326
Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.33069326 10.1016/S0140-6736(20)30925-9
2. Mathers CD Loncar D Projections of global mortality and Burden of Disease from 2002 to 2030 PLoS Med 2006 3 11 e442 10.1371/journal.pmed.0030442 17132052
Mathers CD, Loncar D. Projections of global mortality and Burden of Disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.17132052 10.1371/journal.pmed.0030442
3. Zafari Z Li S Eakin MN Bellanger M Reed RM Projecting Long-Term Health and Economic Burden of COPD in the United States Chest 2021 159 4 1400 10 10.1016/j.chest.2020.09.255 33011203
Zafari Z, Li S, Eakin MN, Bellanger M, Reed RM. Projecting Long-Term Health and Economic Burden of COPD in the United States. Chest. 2021;159(4):1400–10.33011203 10.1016/j.chest.2020.09.255
4. Singh D, Agusti A, Anzueto A et al. Global strategy for the diagnosis, management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5).
5. Hurst JR Vestbo J Anzueto A Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 2010 363 12 1128 38 10.1056/NEJMoa0909883 20843247
Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38.20843247 10.1056/NEJMoa0909883
6. Cho EY Kim SY Kim M-J Comparison of clinical efficacy between ultra-LABAs and ultra-LAMAs in COPD: a systemic review with meta-analysis of randomized controlled trials J Thorac Dis 2018 10 12 6522 30 10.21037/jtd.2018.11.50 30746196
Cho EY, Kim SY, Kim M-J, et al. Comparison of clinical efficacy between ultra-LABAs and ultra-LAMAs in COPD: a systemic review with meta-analysis of randomized controlled trials. J Thorac Dis. 2018;10(12):6522–30.30746196 10.21037/jtd.2018.11.50
7. Donohue JF Betts KA Du EX Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis Int J Chron Obstruct Pulmon Dis 2017 12 367 81 10.2147/COPD.S119908 28176892
Donohue JF, Betts KA, Du EX, et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:367–81.28176892 10.2147/COPD.S119908
8. Donohue JF Niewoehner D Brooks J O’Dell D Church A Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study Respir Res 2014 15 78 10.1186/1465-9921-15-78 25015176
Donohue JF, Niewoehner D, Brooks J, O’Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78.25015176 10.1186/1465-9921-15-78
9. Lee HW Park J Jang EJ Lee C-H Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and bayesian network meta-analysis Respir Res 2020 21 1 1 15 10.1186/s12931-020-01540-8 31898493
Lee HW, Park J, Jang EJ, Lee C-H. Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and bayesian network meta-analysis. Respir Res. 2020;21(1):1–15.31898493 10.1186/s12931-020-01540-8
10. Wedzicha JA Decramer M Ficker JH Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study Lancet Respiratory Med 2013 1 3 199 209 10.1016/S2213-2600(13)70052-3
Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respiratory Med. 2013;1(3):199–209.10.1016/S2213-2600(13)70052-3
11. Calverley PMA Anzueto AR Carter K Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial Lancet Respir Med 2018 6 5 337 44 10.1016/S2213-2600(18)30102-4 29605624
Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–44.29605624 10.1016/S2213-2600(18)30102-4
12. Collins PF Stratton RJ Kurukulaaratchy RJ Elia M Influence of deprivation on health care use, health care costs, and mortality in COPD Int J Chron Obstruct Pulmon Dis 2018 13 1289 96 10.2147/COPD.S157594 29719384
Collins PF, Stratton RJ, Kurukulaaratchy RJ, Elia M. Influence of deprivation on health care use, health care costs, and mortality in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1289–96.29719384 10.2147/COPD.S157594
13. Tottenborg SS Lange P Johnsen SP Nielsen H Ingebrigtsen TS Thomsen RW Socioeconomic inequalities in adherence to inhaled maintenance medications and clinical prognosis of COPD Respir Med 2016 119 160 7 10.1016/j.rmed.2016.09.007 27692139
Tottenborg SS, Lange P, Johnsen SP, Nielsen H, Ingebrigtsen TS, Thomsen RW. Socioeconomic inequalities in adherence to inhaled maintenance medications and clinical prognosis of COPD. Respir Med. 2016;119:160–7.27692139 10.1016/j.rmed.2016.09.007
14. Jenkins CR Celli B Anderson JA Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study Eur Respir J 2012 39 1 38 45 10.1183/09031936.00194610 21737561
Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38–45.21737561 10.1183/09031936.00194610
15. Celli B Vestbo J Jenkins CR Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience Am J Respir Crit Care Med 2011 183 3 317 22 10.1164/rccm.201004-0665OC 20813884
Celli B, Vestbo J, Jenkins CR, et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med. 2011;183(3):317–22.20813884 10.1164/rccm.201004-0665OC
16. Roche N Deslée G Caillaud D Impact of gender on COPD expression in a real-life cohort Respir Res 2014 15 1 20 10.1186/1465-9921-15-20 24533770
Roche N, Deslée G, Caillaud D, et al. Impact of gender on COPD expression in a real-life cohort. Respir Res. 2014;15(1):20.24533770 10.1186/1465-9921-15-20
17. Martinez FJ Curtis JL Sciurba F Sex differences in severe pulmonary emphysema Am J Respir Crit Care Med 2007 176 3 243 52 10.1164/rccm.200606-828OC 17431226
Martinez FJ, Curtis JL, Sciurba F, et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med. 2007;176(3):243–52.17431226 10.1164/rccm.200606-828OC
18. Blais C Jean S Sirois C Quebec Integrated Chronic Disease Surveillance System (QICDSS), an innovative approach Chronic Dis Inj Can 2014 34 4 226 35 10.24095/hpcdp.34.4.06 25408182
Blais C, Jean S, Sirois C, et al. Quebec Integrated Chronic Disease Surveillance System (QICDSS), an innovative approach. Chronic Dis Inj Can. 2014;34(4):226–35.25408182 10.24095/hpcdp.34.4.06
19. Pampalon R Hamel D Gamache P A comparison of individual and area-based socio-economic data for monitoring social inequalities in health Health Rep 2009 20 4 85 94 20108609
Pampalon R, Hamel D, Gamache P. A comparison of individual and area-based socio-economic data for monitoring social inequalities in health. Health Rep. 2009;20(4):85–94.20108609
20. Halbert RJ Natoli JL Gano A Badamgarav E Buist AS Mannino DM Global burden of COPD: systematic review and meta-analysis Eur Respir J 2006 28 3 523 32 10.1183/09031936.06.00124605 16611654
Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–32.16611654 10.1183/09031936.06.00124605
21. Gershon AS Wang C Guan J Vasilevska-Ristovska J Cicutto L To T Identifying individuals with physcian diagnosed COPD in health administrative databases COPD 2009 6 5 388 94 10.1080/15412550903140865 19863368
Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physcian diagnosed COPD in health administrative databases. COPD. 2009;6(5):388–94.19863368 10.1080/15412550903140865
22. Lopez Bernal J Cummins S Gasparrini A The use of controls in interrupted time series studies of public health interventions Int J Epidemiol 2018 47 6 2082 93 10.1093/ije/dyy135 29982445
Lopez Bernal J, Cummins S, Gasparrini A. The use of controls in interrupted time series studies of public health interventions. Int J Epidemiol. 2018;47(6):2082–93.29982445 10.1093/ije/dyy135
23. Murthy SK Begum J Benchimol EI Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study Gut 2020 69 2 274 82 10.1136/gutjnl-2019-318440 31196874
Murthy SK, Begum J, Benchimol EI, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2020;69(2):274–82.31196874 10.1136/gutjnl-2019-318440
24. Bhaskaran K Gasparrini A Hajat S Smeeth L Armstrong B Time series regression studies in environmental epidemiology Int J Epidemiol 2013 42 4 1187 95 10.1093/ije/dyt092 23760528
Bhaskaran K, Gasparrini A, Hajat S, Smeeth L, Armstrong B. Time series regression studies in environmental epidemiology. Int J Epidemiol. 2013;42(4):1187–95.23760528 10.1093/ije/dyt092
25. Langan SM Schmidt SA Wing K Ehrenstein V Nicholls SG Filion KB Klungel O Petersen I Sorensen HT Dixon WG Guttmann A Harron K Hemkens LG Moher D Schneeweiss S Smeeth L Sturkenboom M von Elm E Wang SV Benchimol EI The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) BMJ 2018 363 k3532 10.1136/bmj.k3532 30429167
Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018;363:k3532.30429167 10.1136/bmj.k3532
26. Ismaila AS Haeussler K Czira A Comparative efficacy of Umeclidinium/Vilanterol Versus other bronchodilators for the treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis Adv Ther 2022 39 11 4961 5010 10.1007/s12325-022-02234-x 35857184
Ismaila AS, Haeussler K, Czira A, et al. Comparative efficacy of Umeclidinium/Vilanterol Versus other bronchodilators for the treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis. Adv Ther. 2022;39(11):4961–5010.35857184 10.1007/s12325-022-02234-x
27. Yang M Li Y Jiang Y Guo S He JQ Sin DD Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis Eur Respir J 2023 61 2 2200302 10.1183/13993003.00302-2022 36137586
Yang M, Li Y, Jiang Y, Guo S, He JQ, Sin DD. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. Eur Respir J. 2023;61(2):2200302.36137586 10.1183/13993003.00302-2022
28. Oba Y Keeney E Ghatehorde N Dias S Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis Cochrane Database Syst Rev 2018 12 12 CD012620 30521694
Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2018;12(12):CD012620.30521694
29. Müllerová H Lu C Li H Tabberer M Prevalence and burden of breathlessness in patients with chronic obstructive Pulmonary Disease Managed in Primary Care PLoS ONE 2014 9 1 e85540 10.1371/journal.pone.0085540 24427316
Müllerová H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive Pulmonary Disease Managed in Primary Care. PLoS ONE. 2014;9(1):e85540.24427316 10.1371/journal.pone.0085540
30. Dahl R Jadayel D Alagappan VKT Chen H Banerji D Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study Int J Chron Obstruct Pulmon Dis 2013 8 501 8 10.2147/COPD.S49615 24159259
Dahl R, Jadayel D, Alagappan VKT, Chen H, Banerji D. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis. 2013;8:501–8.24159259 10.2147/COPD.S49615
31. Bateman ED Ferguson GT Barnes N Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study Eur Respir J 2013 42 6 1484 94 10.1183/09031936.00200212 23722616
Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–94.23722616 10.1183/09031936.00200212
32. Schneeweiss S Developments in post-marketing comparative Effectiveness Research Clin Pharmacol Ther 2007 82 2 143 56 10.1038/sj.clpt.6100249 17554243
Schneeweiss S. Developments in post-marketing comparative Effectiveness Research. Clin Pharmacol Ther. 2007;82(2):143–56.17554243 10.1038/sj.clpt.6100249
33. Strange C Walker V Tong J A retrospective claims analysis of dual bronchodilator fixed-dose combination Versus Bronchodilator Monotherapy in patients with Chronic Obstructive Pulmonary Disease Chronic Obstr Pulm Dis 2019 6 3 221 32 31342728
Strange C, Walker V, Tong J, et al. A retrospective claims analysis of dual bronchodilator fixed-dose combination Versus Bronchodilator Monotherapy in patients with Chronic Obstructive Pulmonary Disease. Chronic Obstr Pulm Dis. 2019;6(3):221–32.31342728
34. Wagner AK Soumerai SB Zhang F Ross-Degnan D Segmented regression analysis of interrupted time series studies in medication use research J Clin Pharm Ther 2002 27 4 299 309 10.1046/j.1365-2710.2002.00430.x 12174032
Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299–309.12174032 10.1046/j.1365-2710.2002.00430.x
35. Calzetta L Ritondo BL de Marco P Cazzola M Rogliani P Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies Expert Rev Respir Med 2021 15 1 143 52 10.1080/17476348.2020.1816830 32856967
Calzetta L, Ritondo BL, de Marco P, Cazzola M, Rogliani P. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2021;15(1):143–52.32856967 10.1080/17476348.2020.1816830
36. Puhan MA Gimeno-Santos E Cates CJ Troosters T Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease Cochrane Database Syst Rev 2016 2016 12 CD005305
Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;2016(12):CD005305.
37. Bourbeau J Farias R Li PZ Gauthier G Battisti L Chabot V The Quebec Respiratory Health Education Network: integrating a model of self-management education in COPD primary care Chron Respir Dis 2018 15 2 103 13 10.1177/1479972317723237 28750556
Bourbeau J, Farias R, Li PZ, Gauthier G, Battisti L, Chabot V, et al. The Quebec Respiratory Health Education Network: integrating a model of self-management education in COPD primary care. Chron Respir Dis. 2018;15(2):103–13.28750556 10.1177/1479972317723237
38. Vachon B Giasson G Gaboury I Gaid D De Noël V Houle L Challenges and Strategies for Improving COPD Primary Care Services in Quebec: results of the experience of the COMPAS + quality improvement collaborative Int J Chron Obstruct Pulmon Dis 2022 17 259 72 10.2147/COPD.S341905 35140460
Vachon B, Giasson G, Gaboury I, Gaid D, De Noël V, Houle L, et al. Challenges and Strategies for Improving COPD Primary Care Services in Quebec: results of the experience of the COMPAS + quality improvement collaborative. Int J Chron Obstruct Pulmon Dis. 2022;17:259–72.35140460 10.2147/COPD.S341905
39. Clark AM DesMeules M Luo W Duncan AS Wielgosz A Socioeconomic status and cardiovascular disease: risks and implications for care Nat Rev Cardiol 2009 6 11 712 22 10.1038/nrcardio.2009.163 19770848
Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol. 2009;6(11):712–22.19770848 10.1038/nrcardio.2009.163
40. Cella DF Orav EJ Kornblith AB Socioeconomic status and cancer survival J Clin Oncol 1991 9 8 1500 9 10.1200/JCO.1991.9.8.1500 2072149
Cella DF, Orav EJ, Kornblith AB, et al. Socioeconomic status and cancer survival. J Clin Oncol. 1991;9(8):1500–9.2072149 10.1200/JCO.1991.9.8.1500
41. Alter DA Naylor CD Austin P Tu JV Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction N Engl J Med 1999 341 18 1359 67 10.1056/NEJM199910283411806 10536129
Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med. 1999;341(18):1359–67.10536129 10.1056/NEJM199910283411806
42. Tsiligianni I Mezzi K Fucile S Response to Indacaterol/Glycopyrronium (IND/GLY) by sex in patients with COPD: a pooled analysis from the IGNITE Program COPD 2017 14 4 375 81 10.1080/15412555.2017.1324837 28594587
Tsiligianni I, Mezzi K, Fucile S, et al. Response to Indacaterol/Glycopyrronium (IND/GLY) by sex in patients with COPD: a pooled analysis from the IGNITE Program. COPD. 2017;14(4):375–81.28594587 10.1080/15412555.2017.1324837
43. Wedzicha JA Singh D Tsiligianni I Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study Respir Res 2019 20 1 4 10.1186/s12931-019-0972-7 30621717
Wedzicha JA, Singh D, Tsiligianni I, et al. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. Respir Res. 2019;20(1):4.30621717 10.1186/s12931-019-0972-7
44. Evans J Chen Y Camp PG Bowie DM McRae L Estimating the prevalence of COPD in Canada: reported diagnosis versus measured airflow obstruction Health Rep 2014 25 3 3 11 24648134
Evans J, Chen Y, Camp PG, Bowie DM, McRae L. Estimating the prevalence of COPD in Canada: reported diagnosis versus measured airflow obstruction. Health Rep. 2014;25(3):3–11.24648134
45. Postma DS Rabe KF The Asthma-COPD overlap syndrome N Engl J Med 2015 373 13 1241 9 10.1056/NEJMra1411863 26398072
Postma DS, Rabe KF. The Asthma-COPD overlap syndrome. N Engl J Med. 2015;373(13):1241–9.26398072 10.1056/NEJMra1411863
46. Stringhini S Sabia S Shipley M Association of socioeconomic position with health behaviors and mortality JAMA 2010 303 12 1159 66 10.1001/jama.2010.297 20332401
Stringhini S, Sabia S, Shipley M, et al. Association of socioeconomic position with health behaviors and mortality. JAMA. 2010;303(12):1159–66.20332401 10.1001/jama.2010.297
